Animeloxan 1.5 mg/ml oral suspension for dogs

Authorised

- Meloxicam

Product identification

Medicine name:
Animeloxan 1.5 mg/ml oral suspension for dogs

Active substance:
Meloxicam

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Meloxicam
1.50 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Oral suspension

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AC06

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Netherlands

Available in:
Netherlands

Package description:
(ID3) 100 millilitre(s): Box (Cardboard) with 1 Bottle (Polyethylen hoher Dichte) with 100 millilitre(s), closed with Lid and Verschluss mit Tropfer (Polyethylen, Polyethylen)
(ID1) 10 millilitre(s): Box (Cardboard) with 1 Bottle (Polyethylen hoher Dichte) with 10 millilitre(s), closed with Lid and Verschluss mit Tropfer (Polyethylen, Polyethylen)
(ID6) 125 millilitre(s): Box (Cardboard) with 1 Bottle (Polyethylen hoher Dichte) with 125 millilitre(s), closed with Verschluss mit Tropfer and Lid (Polyethylen, Polyethylen)
(ID4) 25 millilitre(s): Box (Cardboard) with 1 Bottle (Polyethylen hoher Dichte) with 25 millilitre(s), closed with Verschluss mit Tropfer and Lid (Polyethylen, Polyethylen)
(ID5) 50 millilitre(s): Box (Cardboard) with 1 Bottle (Polyethylen hoher Dichte) with 50 millilitre(s), closed with Lid and Verschluss mit Tropfer (Polyethylen, Polyethylen)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
aniMedica GmbH

Marketing authorisation date:

16/09/2008

Manufacturing sites for batch release:
aniMedica GmbH

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 100187

Date of authorisation status change:
8/02/2022

Reference member state:
Germany

Procedure number:
DE/V/0310/001

Concerned member states:
Austria Denmark Hungary Italy Netherlands Poland Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents

English (PDF)

Published on: 13/03/2026

Download

2401060-paren-20240416.pdf